[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556651":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":146,"collaborators":10,"id":148,"slug":10,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":149,"sex":155,"minAge":156,"maxAge":10,"enrollmentInfo":157,"targetDuration":10,"studyType":160,"phases":10,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants cohort",null,"Participants with active LN who initiated belimumab as per local label alongside standard therapy\u002Fies under routine care conditions.",[13],"Other: None (Observational study)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"OTHER","None (Observational study)","Not Applicable since Observational Study",[9],[21],"Observational Study",[23],{"name":24,"affiliation":5,"role":25},"GSK Clinical Trials","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":31},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[36,58,72,86,100,115,131],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"GSK Investigational Site","RECRUITING","Baltimore","Maryland","21287","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-76.61219,39.29038,{"lat":48,"lon":47},[51,52,55],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":56,"role":57,"phone":10,"phoneExt":10,"email":10},"Michelle Petri","PRINCIPAL_INVESTIGATOR",{"facility":37,"status":38,"city":59,"state":60,"zip":61,"country":42,"countryCode":43,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Charlotte","North Carolina","28207",{"type":45,"coordinates":63},[64,65],-80.84313,35.22709,{"lat":65,"lon":64},[68,69,70],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},{"name":71,"role":57,"phone":10,"phoneExt":10,"email":10},"Gordon Lam",{"facility":37,"status":38,"city":73,"state":74,"zip":75,"country":42,"countryCode":43,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Columbus","Ohio","43201",{"type":45,"coordinates":77},[78,79],-82.99879,39.96118,{"lat":79,"lon":78},[82,83,84],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},{"name":85,"role":57,"phone":10,"phoneExt":10,"email":10},"Isabelle Ayoub",{"facility":37,"status":38,"city":87,"state":88,"zip":89,"country":42,"countryCode":43,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Hixson","Tennessee","37343-7908",{"type":45,"coordinates":91},[92,93],-85.23273,35.14063,{"lat":93,"lon":92},[96,97,98],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},{"name":99,"role":57,"phone":10,"phoneExt":10,"email":10},"Joseph Huffstutter",{"facility":37,"status":38,"city":101,"state":10,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Marseille","13005","France","FR",{"type":45,"coordinates":106},[107,108],5.38107,43.29695,{"lat":108,"lon":107},[111,112,113],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},{"name":114,"role":57,"phone":10,"phoneExt":10,"email":10},"Noemie Jourde Chiche",{"facility":37,"status":38,"city":116,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Rozzano","Milan","20089","Italy","IT",{"type":45,"coordinates":122},[123,124],9.1559,45.38193,{"lat":124,"lon":123},[127,128,129],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},{"name":130,"role":57,"phone":10,"phoneExt":10,"email":10},"Francesco Reggiani",{"facility":37,"status":38,"city":132,"state":10,"zip":133,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Fukuoka","807-8556","Japan","JP",{"type":45,"coordinates":137},[138,139],130.41667,33.6,{"lat":139,"lon":138},[142,143,144],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":54,"phoneExt":10,"email":31},{"name":145,"role":57,"phone":10,"phoneExt":10,"email":10},"Shingo Nakayamada",{"type":147,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100556651",false,"NCT06527872","Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN","The Evaluation Of Use of Belimumab in Routine Care SEttings in Lupus Nephritis (LN): the OBSErve-LN Study","OBSErve-LN","Inclusion Criteria:\n\n* Participants to provide a signed informed consent at the time of enrollment per protocol,\n* Male or female aged 18 or over at initiation of belimumab,\n* Participants received belimumab in any formulation (subcutaneous or intravenous) for the treatment of active LN prescribed as per local label in combination with standard immunosuppressive therapy\u002Fies at initiation of belimumab,\n* Participants initiated belimumab 6 to 24 months prior to study enrollment,\n* Accessibility of medical records starting at belimumab initiation (including accessibility of medical records for the prior 12 months and confirmatory biopsy at any time prior to belimumab initiation),\n* Biopsy-confirmed LN diagnosis at any time prior to belimumab initiation for treatment of LN\n* Class III (focal LN) with or without Class V (membranous LN),\n* Class IV (diffuse LN) with or without Class V,\n* Class V.\n\nExclusion Criteria:\n\n* Participants receiving renal replacement therapy (i.e., dialysis, kidney transplant, or those in end-stage kidney disease) at initiation of belimumab,\n* Participant is concomitantly receiving another SLE targeted monoclonal antibody (MAb), or a MAb expected to compromise immune responses, at initiation of belimumab,\n* Participants in a clinical trial during the observation period (with the exception of allowing participation in other non-interventional studies),\n* Participant is pregnant at the initiation of belimumab,\n* Participant with a kidney transplant at the initiation of belimumab,\n* Participants will be excluded from the study if they are planning to become pregnant or are pregnant at study enrollment.","ALL","18 Years",{"count":158,"type":159},300,"ESTIMATED","OBSERVATIONAL","The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.",[163],"Lupus Nephritis",[165,166,153,167,168],"Belimumab","Lupus nephritis","Renal function","Real world data","2026-07-01",{"date":171,"type":172},"2026-07-02","ACTUAL",{"date":174,"type":172},"2024-10-04",{"date":176,"type":159},"2029-03-29",{"name":5,"class":6},7]